GleamWall
中文EN

JANX Janux Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1817713 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY132.9%
TTM net income YoY2.0%
TTM EPS YoY4.8%
Revenue 3-yr CAGR40.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-599.3%
Net margin-428.7%
FCF margin-232.6%
EBITDA margin-591.3%

Returns

ROE-10.6%
ROA-9.9%
ROIC (approx.)-12.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets7.3%
Debt / equity0.00x
Current ratio17.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.54x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.29M$10.27M$3.73M$0$10.00M$0$0$0
R&D expense$30.57M$30.99M$26.81M$31.55M$34.63M$34.66M$25.05M$20.81M
SG&A expense$9.98M$10.96M$11.13M$10.85M$10.62M$10.45M$9.84M$8.22M
Operating income-$31.26M-$31.69M-$34.21M-$42.40M-$35.25M-$45.12M-$34.90M-$29.02M
Net income-$21.57M-$21.97M-$24.36M-$31.95M-$24.31M-$33.86M-$23.51M-$20.22M
EBITDA-$30.80M-$31.23M-$33.74M-$41.93M-$34.75M-$44.58M-$34.38M-$28.51M
EPS (basic)-0.34-0.35-0.39—-0.39-0.55-0.38—
EPS (diluted)-0.34-0.35-0.39—-0.39-0.55-0.38—
Weighted avg. shares (diluted)63.09M62.94M62.67M—62.02M61.90M61.79M—
Balance sheet
Cash & equivalents$41.82M$27.77M$51.83M$52.33M$48.39M$52.45M$73.74M$430.61M
Short-term investments$903.90M$943.14M$904.56M$914.23M$940.60M$943.57M$940.40M$594.57M
Receivables$411,000$149,000$35.00M$0————
Current assets$959.38M$983.34M$1.00B$975.89M$998.09M$1.01B$1.02B$1.03B
PP&E, net$2.79M$3.26M$3.55M$3.85M$4.31M$4.69M$4.95M$4.86M
Total assets$983.65M$1.01B$1.03B$1.00B$1.02B$1.03B$1.05B$1.06B
Current liabilities$54.25M$60.15M$58.91M$25.00M$27.83M$21.38M$17.50M$17.46M
Total liabilities$72.04M$79.67M$86.69M$44.74M$48.21M$41.70M$38.30M$38.73M
Shareholders' equity$911.61M$927.98M$941.53M$956.82M$976.55M$990.52M$1.01B$1.02B
Shares outstanding61.17M61.08M60.87M60.38M60.12M59.30M59.17M59.06M
Cash flow statement
Operating cash flow-$25.18M$12.48M-$12.34M-$28.54M-$12.86M-$23.81M-$17.02M-$16.73M
Capital expenditure$2,000$202,000$273,000$106,000$93,000$473,000$371,000$42,000
Free cash flow-$25.18M$12.28M-$12.61M-$28.65M-$12.95M-$24.29M-$17.39M-$16.77M
Investing cash flow$38.38M-$38.78M$8.29M$29.54M$8.31M$1.56M-$340.39M$33.93M
Financing cash flow$852,000$2.24M$3.54M$2.94M$493,000$954,000$554,000$386.65M
Depreciation & amortization$458,000$463,000$469,000$468,000$501,000$541,000$519,000$512,000
Stock-based compensation$8.54M$9.06M$9.27M$9.52M$9.04M$10.96M$10.70M$6.25M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.